Company
Recursion Pharmaceuticals, Inc.
Headquarters: Salt Lake City, UT, United States
Employees: 330
CEO: Dr. Christopher C. Gibson Ph.D.
Market Cap
$2.14 Billion
USD as of July 1, 2025
Recursion Pharmaceuticals, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | $59.8 M |
| EBITDA | $-525,584,000 |
| Gross Profit TTM | $-372,606,016 |
| Profit Margin | 22.65% |
| Operating Margin | -1297.85% |
| Quarterly Revenue Growth | 6.90% |
Stocks & Indices
Recursion Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: RXRX wb_incandescent